CA2087883A1 - Beta-alethine use in cell culture and therapy - Google Patents

Beta-alethine use in cell culture and therapy

Info

Publication number
CA2087883A1
CA2087883A1 CA 2087883 CA2087883A CA2087883A1 CA 2087883 A1 CA2087883 A1 CA 2087883A1 CA 2087883 CA2087883 CA 2087883 CA 2087883 A CA2087883 A CA 2087883A CA 2087883 A1 CA2087883 A1 CA 2087883A1
Authority
CA
Canada
Prior art keywords
cell
alethine
beta
mammal
immunocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2087883
Other languages
French (fr)
Other versions
CA2087883C (en
Inventor
Galen D. Knight
Paul L. Mann
Terence J. Scallen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of New Mexico UNM
Original Assignee
University of New Mexico UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of New Mexico UNM filed Critical University of New Mexico UNM
Priority to CA002481077A priority Critical patent/CA2481077A1/en
Publication of CA2087883A1 publication Critical patent/CA2087883A1/en
Application granted granted Critical
Publication of CA2087883C publication Critical patent/CA2087883C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE
.beta.-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of .beta.-alethine in the treatment of immune disorders and diseases, especially neoplasia, and in the promotion of cell cultures.

Claims (15)

1. A method for regulating cell function or bioproduction comprising exposing the cell, in vitro or in vivo, to an amount of .beta.-alethine, or physiologically compatible salt thereof, sufficient to normalize or improve function or bioproduction of the cell.
2. The method of Claim 1, wherein the cell is mammalian, including a human cell.
3. The method of Claim 2, wherein the cell is infected with a pathogen, including a virus.
4. The method of Claim 2, wherein the cell is an immunocyte or a neoplastic cell.
5. The method of Claim 1, wherein the cell is an immunocyte exposed to sufficient .beta.-alethine to normalize or improve immunological surveillance.
6. The method of Claim 1, wherein the cell is exposed, in vitro, to from at least about 10 pg .beta.-alethine/ml cell culture, or, in vivo, from at least about 10 pg .beta.-alethine/kg weight of the organism.
7. A method for treating neoplasia in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount suffi-cient to reduce tumor burden, induce regression of the tumor, or inhibit tumor growth or metastasis, optionally in conjunction with debulking of a tumor.
8. The method of Claim 7, wherein the neoplasia is hematolymphoid.
9. A method for treating immune disease or disorder in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount sufficient to improve or normalize immunological function or bioproduction in the mammal.
10. The method of Claim 9, wherein the immune disease or disorder is an autoimmune disease or disorder, or an immunodefi-ciency disease or disorder, including AIDS or hypogammaglobuli-nemia.
11. The method of Claim 1 for improving or normalizing immunocyte function or bioproduction in a mammal, including a human, comprising extracting an immunocyte from the mammal, exposing the immunocyte, in vitro, or sufficient .beta.-alethine to stimulate immune function or bioproduction thereof, and thereaf-ter reintroducing the stimulated immunocyte into the afflicted mammal.
12. The method of Claim 11, wherein the mammal is afflicted with neoplasia, and the immunocyte is additionally stimulated by exposure to the neoplastic cell prior to the reintroduction of the immunocyte into the mammal.
13. A method for delaying the onset of senescence comprising exposing a presenescent cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to delay senescence thereof.
14. A method for adapting a culture-resistant cell of an organism to culture, comprising exposing the resistant cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to adapt the cell to culture.
15. The method of Claim 1, wherein a cell of an organism is additionally exposed to at least one factor which promotes either the maintenance or growth of the cell, or both.
CA 2087883 1992-07-27 1993-01-22 Beta-alethine use in cell culture and therapy Expired - Lifetime CA2087883C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002481077A CA2481077A1 (en) 1992-07-27 1993-01-22 Beta-alethine use in cell culture and therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91925392A 1992-07-27 1992-07-27
US07/919,253 1992-07-27
US92497792A 1992-08-05 1992-08-05
US07/924,977 1992-08-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002481077A Division CA2481077A1 (en) 1992-07-27 1993-01-22 Beta-alethine use in cell culture and therapy

Publications (2)

Publication Number Publication Date
CA2087883A1 true CA2087883A1 (en) 1994-01-28
CA2087883C CA2087883C (en) 2010-09-14

Family

ID=27129768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2087883 Expired - Lifetime CA2087883C (en) 1992-07-27 1993-01-22 Beta-alethine use in cell culture and therapy

Country Status (1)

Country Link
CA (1) CA2087883C (en)

Also Published As

Publication number Publication date
CA2087883C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
Koenig et al. Bacterial lipopolysaccharide activates suppressor B lymphocytes.
CN103736207B (en) A kind of based on the synergistic bone injury/osteoporosis therapeutic bed of many physical agents
EP0308197A3 (en) Method for stimulating the immune system
Dwarakanath et al. Modification of the radiation induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas
Argall et al. Interactions between CD4+ T-cells and rat Schwann cells in vitro: 1. Antigen presentation by Lewis rat Schwann cells to P2-specific CD4+ T-cell lines
CA2087883A1 (en) Beta-alethine use in cell culture and therapy
GR3018632T3 (en) Beta-alethine use in cell culture and therapy.
RU94022481A (en) Method of estimation of immunogenic activity of bioactive compounds and composition for its realization
HU189706B (en) Improved process for the production of interferon
Lamberts et al. Effect of cyproheptadine, desmethylcyproheptadine, γ-amino-butyric acid and sodium valproate on adrenocorticotrophin secretion by cultured pituitary tumour cells from three patients with Nelson's syndrome
Holmes et al. The radiation dose-rate effect in two human neuroblastoma cell lines
Cory et al. Calcium ion-dependent proliferation of L1210 cells in culture
Cercek et al. Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix.
Barkley Jr et al. Volume and time factors in interstitial gamma-ray therapy
Zhong et al. Control and surveillance of filariasis in Shandong
CN103736209A (en) Osteoporosis treatment bed based on medium wave ultraviolet light exposure
Giacovazzo et al. Relationship between HLA system in cluster headache and clinical response to lithium therapy
Morgan et al. Malignancy in vivo of chick embryo cells infected with Rous sarcoma virus in vitro
JPS6461420A (en) Alpha-ethiocholanedione drug, and method of causing high hematic concentration alpha-ethiocholanone
Laude et al. Isoprinosine trial in herpes zoster. Effects on delayed cutaneous hypersensitivity
Ahrorovna Morphological Features of Lymphoid Structures of the Small Intestine of Rats in Norm and Chronic Radiation Sickness
Levo et al. Increased incidence of urethane induced lung adenomata by autosensitized lymphocytes
Wierowski et al. Critical periods during the in situ repair of radiation-induced DNA damage in rat cerebellar neurons and 9L brain tumor cells
Galbraith Effect of lithium on colony formation and production of colony-stimulating factor
Naumov et al. Autonomous device for photostimulation of the gastrointestinal tract immunity

Legal Events

Date Code Title Description
EEER Examination request
FZDC Correction of dead application (reinstatement)
MKEX Expiry

Effective date: 20130122